AMGEN INC AMGN
Nasdaq · XNAS · stock · Biological Products, (No Diagnostic Substances)
Chart by TradingView
6/9
Piotroski F — financial health
0.14
Altman Z″ — distress risk · distress
66.5%
Dividend payout · stretched
Financials (annual, from 10-K)
| FY | Revenue | Net income | Gross profit | Free cash flow | Equity |
|---|---|---|---|---|---|
| 2025 | $36.8B | $7.7B | — | $8.1B | $8.7B |
| 2024 | $33.4B | $4.1B | — | $10.4B | $5.9B |
| 2023 | $28.2B | $6.7B | — | $7.4B | $6.2B |
| 2022 | $26.3B | $6.6B | — | $8.8B | $3.7B |
| 2021 | $26.0B | $5.9B | — | $8.4B | $6.7B |
| 2020 | $25.4B | $7.3B | — | $9.9B | $9.4B |
Recent insider activity (Form 4)
| Insider | Role | Date | Action | Shares | Price |
|---|---|---|---|---|---|
| MILES AMY E | director | 2026-05-19 | Grant | 665 | — |
| Kullman Ellen Jamison | director | 2026-05-19 | Grant | 665 | — |
| Klotman Mary E. | director | 2026-05-19 | Grant | 665 | — |
| Jacks Tyler | director | 2026-05-19 | Grant | 665 | — |
| ISHRAK OMAR | director | 2026-05-19 | Grant | 665 | — |
| HOLLEY CHARLES M | director | 2026-05-19 | Grant | 665 | — |
| Garland Greg C. | director | 2026-05-19 | Grant | 665 | — |
| ECKERT ROBERT | director | 2026-05-19 | Grant | 665 | — |
Why these scores methodology →
Piotroski F-score: 6/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: 0.14 (distress)
- Working capital / assets 0.039
- Retained earnings / assets -0.277
- EBIT / assets 0.1
- Equity / liabilities 0.106
Source: SEC EDGAR filings · CIK 0000318154 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.